Beispiel: Heart Attack

Klinische Studien gesponsert von Agennix

Insgesamt 20 ergebnisse

NCT01273779

Suspendiert

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

Bedingungen: Severe Sepsis
NCT01168882

Zurückgezogen

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

Bedingungen: Hematological Malignancies
NCT00854633

Unbekannter Status

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

Bedingungen: Nosocomial Infections
NCT00707304

Abgeschlossen

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

Bedingungen: Non Small Cell Lung Cancer
NCT00706862

Unbekannter Status

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Bedingungen: Non Small Cell Lung Cancer
NCT00630656

Abgeschlossen

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Bedingungen: Severe Sepsis
NCT00480623

Beendet

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Bedingungen: Prostate Cancer
NCT00450970

Beendet

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Bedingungen: Prostate Cancer
NCT00370383

Abgeschlossen

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Bedingungen: Lung Cancer
NCT00329329

Beendet

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Bedingungen: Malignancies
NCT00313456

Beendet

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Bedingungen: Tumors; Prostate Cancer
NCT00268970

Abgeschlossen

Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Bedingungen: Non-small Cell Lung Cancer
NCT00265655

Abgeschlossen

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

Bedingungen: Metastatic Breast Cancer
NCT00125411

Beendet

Study of Satraplatin (JM-216) in Combination With Docetaxel

Bedingungen: Tumors
NCT00095186

Abgeschlossen

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

Bedingungen: Carcinoma, Renal Cell
NCT00093132

Beendet

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

Bedingungen: Carcinoma, Non-small Cell Lung; Lung Cancer
NCT00069745

Abgeschlossen

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Bedingungen: Prostate Cancer; Hormone Refractory Prostate Cancer
NCT00473720

Abgeschlossen

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Bedingungen: Advanced Cancers
NCT01220284

Unbekannter Status

Satraplatin and Vinorelbine in Advanced Solid Tumors

Bedingungen: Advanced Solid Tumors
NCT01528137

Beendet

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Bedingungen: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Non-small Cell Lung Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer